Medicenna Therapeutics (MDNA) investor relations material

Strategic focus and platform development

• Focused on developing immunotherapies for late-stage cancers and immune-related diseases using engineered cytokines called Superkines.

• Licensed exclusive worldwide rights to Superkines from Stanford in 2016 and IPO'd on TSX in 2017.

• Clinical collaboration with Merck to combine their drug KEYTRUDA with Superkines.

• De-risked development with FDA agreement on phase III design for brain cancer drug and over 100 patient data points.

• Team includes leading experts in brain and skin cancer, with decades of biotech experience.

Pipeline highlights and clinical progress

• MDNA55 (Bizaxofusp) for brain cancer is phase III ready and seeking partnership.

• MDNA113, a checkpoint inhibitor fused to IL-2, is entering the clinic next year; similar compounds have seen major deals, e.g., Takeda-Innovent ($11.2B).

• MDNA11, an IL-2 super agonist, is in phase 2 with over 100 patients treated; data to be presented in December.

• MDNA113 will have non-human primate data before clinical entry next year.

• MDNA11 phase 1 completed; phase 2 ongoing, focusing on tumor shrinkage and safety.

Clinical data and competitive positioning

• MDNA11 enables treatment every 2-3 weeks, showing tumor shrinkage or cures in patients who failed KEYTRUDA and other therapies.

• Achieves 30%-50% tumor shrinkage rates in refractory patients, outperforming KEYTRUDA (16%) and Bristol Myers' combo (20%).

• Engineered for 100x better binding to immune cells and longer bloodstream presence via albumin fusion.

• Demonstrated durable responses, including complete remission in pancreatic and melanoma patients, with outpatient treatment and favorable safety.

• Clinical benefit rate (tumor shrinkage or stabilization) is about 60%.